Blog
Retatrutide vs Tirzepatide vs Semaglutide: Key Research Differences
Retatrutide vs Tirzepatide vs Semaglutide: What Is the Difference?
Retatrutide, tirzepatide and semaglutide are three important compounds in modern metabolic research, but they are not pharmacologically identical.
The biggest difference is their receptor activity:
- Semaglutide: GLP-1 receptor agonist
- Tirzepatide: GIP and GLP-1 receptor agonist
- Retatrutide: GIP, GLP-1 and glucagon receptor agonist
This progression from single-receptor to dual-receptor and triple-receptor activity is one of the reasons retatrutide has attracted substantial scientific interest.
Retatrutide remains investigational, while semaglutide and tirzepatide have FDA-approved products for specific indications.
Quick Comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Research category | GLP-1 agonist | Dual GIP/GLP-1 agonist | Triple GIP/GLP-1/glucagon agonist |
| GLP-1 activity | Yes | Yes | Yes |
| GIP activity | No | Yes | Yes |
| Glucagon receptor activity | No | No | Yes |
| Research identifier | Semaglutide | Tirzepatide | LY3437943 |
| Development status | Approved products available | Approved products available | Investigational |
| Scientific interest | GLP-1 signalling | Dual incretin signalling | Triple-receptor signalling |
Tirzepatide’s FDA-approved mechanism involves activation of both GIP and GLP-1 receptors, whereas semaglutide is a GLP-1 receptor agonist.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist that has been extensively studied in diabetes and obesity-related research.
GLP-1 signalling is involved in glucose regulation, appetite and gastrointestinal activity. FDA-approved semaglutide products include Ozempic, Rybelsus and Wegovy for specific indications.
In March 2026, the FDA also approved a higher-dose Wegovy formulation, Wegovy HD, for certain adults with obesity or overweight with a weight-related condition.
Semaglutide Research Focus
Scientific research involving semaglutide includes:
- GLP-1 receptor signalling
- glucose regulation
- appetite-related pathways
- body-weight regulation
- cardiometabolic research
- obesity research
- type 2 diabetes research
Semaglutide therefore represents the single-receptor GLP-1 model in this comparison.
What Is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist.
Unlike semaglutide, which primarily activates the GLP-1 receptor, tirzepatide activates both the GIP and GLP-1 receptors. FDA documentation describes tirzepatide as a GIP and GLP-1 receptor agonist.
Tirzepatide is marketed in the United States as Mounjaro for type 2 diabetes and Zepbound for chronic weight management in certain adults.
Tirzepatide Research Focus
Research has examined:
- GIP receptor signalling
- GLP-1 receptor signalling
- glucose-dependent insulin secretion
- glucagon regulation
- appetite-related pathways
- body-weight regulation
- cardiometabolic outcomes
The addition of GIP receptor activity is the major pharmacological distinction between tirzepatide and semaglutide.
What Is Retatrutide?
Retatrutide, also known as LY3437943, is an investigational compound being developed by Eli Lilly.
It is different from both semaglutide and tirzepatide because it is being studied as a triple receptor agonist.
Retatrutide targets:
- GLP-1 receptors
- GIP receptors
- Glucagon receptors
Lilly describes retatrutide as a first-in-class triple receptor agonist and continues to evaluate it in Phase 3 clinical development.
Why Is Retatrutide Different?
The addition of glucagon receptor activity is the defining difference.
The simplified progression is:
Semaglutide → GLP-1
Tirzepatide → GIP + GLP-1
Retatrutide → GIP + GLP-1 + glucagon
This makes retatrutide particularly interesting for researchers studying the interaction between incretin signalling, glucagon biology and energy metabolism.
Retatrutide vs Tirzepatide
The primary difference is the number of receptor pathways involved.
Tirzepatide activates:
- GIP
- GLP-1
Retatrutide is being investigated for activity at:
- GIP
- GLP-1
- glucagon
Therefore, retatrutide adds glucagon receptor activity to the dual GIP/GLP-1 mechanism found with tirzepatide.
This does not, however, mean that a triple agonist should automatically be considered superior to a dual agonist. Different mechanisms can produce different pharmacological profiles, and comparative conclusions require appropriate clinical evidence.
Retatrutide vs Semaglutide
The mechanistic difference is even more pronounced.
Semaglutide primarily targets the GLP-1 receptor, while retatrutide is being investigated for simultaneous GIP, GLP-1 and glucagon receptor activity.
This makes the comparison useful for understanding the development of increasingly multi-targeted metabolic compounds.
Semaglutide has an established clinical-development and regulatory history, whereas retatrutide remains investigational.
Tirzepatide vs Semaglutide
Tirzepatide and semaglutide are both widely studied metabolic compounds, but their receptor profiles differ.
Semaglutide: GLP-1
Tirzepatide: GIP + GLP-1
The FDA describes tirzepatide as a dual GIP/GLP-1 receptor agonist, while semaglutide belongs to the GLP-1 receptor agonist class.
This difference is central to research comparing single-pathway and dual-pathway incretin activity.
Which One Has the Most Advanced Regulatory Status?
This is an important distinction.
Semaglutide
Semaglutide has FDA-approved products for specific indications, including type 2 diabetes and chronic weight management.
Tirzepatide
Tirzepatide has FDA-approved products for specific indications, including type 2 diabetes and chronic weight management.
Retatrutide
Retatrutide is still investigational.
The FDA specifically states that retatrutide is not an approved component of an FDA-approved drug and has not been found safe and effective for any condition.
Therefore, retatrutide should not be presented as equivalent to an approved semaglutide or tirzepatide medicine.
Why Is Retatrutide Receiving So Much Research Attention?
The major scientific attraction is its triple-receptor mechanism.
Researchers are investigating whether simultaneously influencing GIP, GLP-1 and glucagon pathways can produce a distinct metabolic profile.
Lilly reported Phase 3 results in 2026 involving obesity and type 2 diabetes populations, demonstrating continued advancement of the retatrutide clinical-development programme.
However, clinical-trial results should not be interpreted as evidence that non-approved commercial retatrutide products are safe or effective.
Are Retatrutide, Tirzepatide and Semaglutide the Same?
No.
Although all three are peptide-based compounds studied in metabolic research, their receptor profiles are different.
Semaglutide = GLP-1
Tirzepatide = GIP + GLP-1
Retatrutide = GIP + GLP-1 + glucagon
These mechanistic differences are important when interpreting scientific literature and comparing clinical-development programmes.
Research-Use Considerations
Researchers evaluating peptide materials should distinguish between:
- an investigational research compound;
- an FDA-approved pharmaceutical;
- a compounded drug;
- and a laboratory research material.
FDA has specifically warned about unapproved versions of GLP-1-related drugs and notes that unapproved products have not undergone FDA review for safety, effectiveness and quality before marketing.
For laboratory research, product identity, batch information, analytical documentation and applicable laboratory handling procedures should be independently verified.
Retatrutide vs Tirzepatide vs Semaglutide: Final Comparison
The simplest way to understand the three compounds is through their receptor targets.
Semaglutide represents a GLP-1 receptor approach.
Tirzepatide expands that approach by targeting both GIP and GLP-1 receptors.
Retatrutide goes one step further by being investigated as a GIP, GLP-1 and glucagon receptor agonist.
That makes these compounds particularly useful for understanding the evolution of metabolic peptide research from single-pathway → dual-pathway → triple-pathway receptor activity.
For Remedium Research, this distinction is important when discussing research compounds, scientific literature and product specifications without confusing investigational materials with approved medicines.
Frequently Asked Questions
Is retatrutide the same as tirzepatide?
No. Tirzepatide activates GIP and GLP-1 receptors, while retatrutide is being investigated as a GIP, GLP-1 and glucagon receptor agonist.
Is retatrutide the same as semaglutide?
No. Semaglutide is a GLP-1 receptor agonist, while retatrutide targets three receptor pathways.
What is the difference between tirzepatide and semaglutide?
Tirzepatide activates GIP and GLP-1 receptors, whereas semaglutide primarily activates the GLP-1 receptor.
What does LY3437943 mean?
LY3437943 is the development identifier for retatrutide.
Is retatrutide FDA approved?
No. Retatrutide remains investigational.
Are semaglutide and tirzepatide FDA approved?
Yes, specific semaglutide and tirzepatide products have FDA-approved indications.
Why is retatrutide called a triple agonist?
Because it is being investigated for activity at the GIP, GLP-1 and glucagon receptors.
What is the main research difference between the three?
Their receptor profiles:
Semaglutide: GLP-1
Tirzepatide: GIP + GLP-1
Retatrutide: GIP + GLP-1 + glucagon
Research Use Only: This article is provided for educational and scientific research information. Investigational compounds should not be represented as approved medicines or treatments. This content does not provide medical advice, diagnosis, treatment recommendations or human-use instructions.
